Results 271 to 280 of about 14,106,540 (324)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Immobilization of Ca<sup>2+</sup> by OH<sup>-</sup> ions on calcium silicate hydrates.

open access: yesPhys Chem Chem Phys
Casar Z   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy